A Long-term Safety Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes

NCT03861039 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

443

Enrollment

INDUSTRY

Sponsor class

Conditions

Type 2 Diabetes Mellitus

Interventions

DRUG: Tirzepatide
DRUG: Oral antihyperglycemic medication (OAM)

Sponsor

Eli Lilly and Company